Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate SARS-CoV-2RNA Detection in Persons With COVID-19

Next Previous
Trial Profile

A Phase IIa Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Safety, Tolerability and Efficacy of EIDD-2801 to Eliminate SARS-CoV-2RNA Detection in Persons With COVID-19

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 16 May 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Molnupiravir (Primary)
  • Indications SARS-CoV-2 acute respiratory disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Ridgeback Biotherapeutics

Most Recent Events

  • 23 Nov 2021 Results assessing the comprehensive analysis of demographic, immunologic, virologic, and clinical disease factors associated with infectious virus isolation and levels of viral RNA in nasopharyngeal swab samples in the largest study of symptomatic outpatient adults with COVID-19, published in the Clinical Infectious Diseases.
  • 10 Mar 2021 Results presented at the 28th Conference on Retroviruses and Opportunistic Infections
  • 06 Mar 2021 According to a Merck media release, findings from the primary efficacy and safety endpoints and additional secondary objectives will be presented at an upcoming medical meeting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top